Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | DTYMK | P23919 | 1/20 | 0.44 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.44 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4160782 | 0.84 | KMT2A (0.64) | GRIA1GRIA2GRIA4GRIK5KMT2A | |
| SCHEMBL7643586 | 0.82 | MAPK1 (0.51) | KMT2A | |
| SCHEMBL28641604 | 0.82 | ALDH1A1 (0.48) | GRIA1GRIA2GRIA4GRIK5KMT2A | |
| SCHEMBL2153060 | 0.81 | GRIA1 (0.60) | GRIA1GRIA2GRIA4GRIK5KMT2A | |
| SCHEMBL7718378 | 0.81 | KMT2A (0.52) | GRIA1GRIA2GRIA4GRIK5KMT2A | |
| SCHEMBL19873691 | 0.74 | GRIA1 (0.52) | GRIA1GRIA2GRIA4GRIK5KMT2A | |
| SCHEMBL21637700 | 0.74 | LMNA (0.53) | GRIA1GRIA2GRIA4GRIK5KMT2A | |
| SCHEMBL28660748 | 0.73 | SMN1; SMN2 (0.51) | KMT2AMEN1CYP1A2CYP2C19 | |
| SCHEMBL21695465 | 0.73 | LMNA (0.71) | GRIA1GRIA2GRIA4GRIK5KMT2A | |
| SCHEMBL28660743 | 0.73 | UPP1 (0.58) | KMT2AMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3708566-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2023-02-08 | — | — | EP | disclosed |
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| US-7378485-B2 | Peptide nucleic acids with polyamide-containing backbones | BUCHARDT OLE | 2008-05-27 | — | — | US | disclosed |
| EP-0773950-B1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-0773950-B1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060160731-A1 | Peptide nucleic acids | BUCHARDT OLE | 2006-07-20 | — | — | US | disclosed |
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | BUCHARDT OLE (DK) | 2005-01-13 | — | — | US | disclosed |
| EP-1411063-A1 | Peptide nucleic acids | BUCHARDT, Ole (DK) | 2004-04-21 | — | — | EP | disclosed |
| US-6713602-B1 | COMPOUNDS THAT ARE NOT POLYNUCLEOTIDES YET WHICH BIND TO COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY THE CORRESPONDING DNA | BUCHARDT OLE (DK) | 2004-03-30 | — | — | US | disclosed |
| US-20040059087-A1 | Peptide nucleic acids | BUCHARDT OLE (DK) | 2004-03-25 | — | — | US | disclosed |
| US-6395474-B1 | COMPOUND FOR USE IN HUMAN THERAPEUTICS AND DIAGNOSTICS | BUCHARDT OLE (DK) | 2002-05-28 | — | — | US | disclosed |
| EP-1162206-A2 | Peptide nucleic acids | BUCHARDT, Ole (DK) | 2001-12-12 | — | — | EP | disclosed |
| EP-0586474-B1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 2001-09-12 | — | — | EP | disclosed |
| US-6228982-B1 | STABLE COMPOUNDS THAT FORM DOUBLE-STRANDED, HELICAL STRUCTURES MIMICKING DOUBLE-STRANDED DNA; DIAGNOSIS; PROPHYLAXIS; THERAPY; ANTISENSE AGENTS | NIELSEN, PETER E. (DK) | 2001-05-08 | — | — | US | disclosed |
| EP-1074559-A1 | Peptide nucleic acids | BUCHARDT, Ole (DK) | 2001-02-07 | — | — | EP | disclosed |
| EP-0773950-A4 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS INC (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0773950-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996002558-A1 | LINKED PEPTIDE NUCLEIC ACIDS | ISIS PHARMACEUTICALS, INC. (US) | 1996-02-01 | — | — | WO | disclosed |
| EP-0586474-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT, Ole (DK) | 1994-03-16 | — | — | EP | disclosed |
| WO-1992020702-A1 | PEPTIDE NUCLEIC ACIDS | BUCHARDT OLE (DK) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | POLRMT, CPSF7, RNGTT | GRIA1 2233/4885GRIA2 3346/4885GRIA4 3381/4885 |
| US-20060160731-A1 | Peptide nucleic acids | RNGTT, POLM, POLRMT | GRIA1 2393/4885GRIA2 2870/4885GRIA4 3047/4885 |
| US-20040059087-A1 | Peptide nucleic acids | RNGTT, POLM, POLRMT | GRIA1 2393/4885GRIA2 2870/4885GRIA4 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.